Podcasts about PAH

In the second episode of our Rare Lung Diseases podcast mini-series, host Saranya Ravindran delves into the complexities of pulmonary arterial hypertension (PAH) with Neal Chaisson, Assistant Professor of Medicine at the Cleveland Clinic. Chaisson shares insights into why PAH remains under-recognised, the nuances of detection and diagnosis, and what the latest advancements mean for patients and clinicians. The discussion covers everything from early warning signs to future directions in PAH management and research. Tinestamps: 00:45 – PAH management 03:05 – Hypoxia 06:42 – Decompensated PAH 10:06 – At-home treatments 12:44 – Multidisciplinary teams 14:50 – Novel therapies

In the second episode of our Rare Lung Diseases podcast mini-series, host Saranya Ravindran delves into the complexities of pulmonary arterial hypertension (PAH) with Neal Chaisson, Assistant Professor of Medicine at the Cleveland Clinic. Chaisson shares insights into why PAH remains under-recognised, the nuances of detection and diagnosis, and what the latest advancements mean for patients and clinicians. The discussion covers everything from early warning signs to future directions in PAH management and research. Timestamps: 01:05 – Diagnostic workflows 03:58 – Non-invasive tools 05:37 – Right heart catheterisation values 09:05 – Vasoreactivity testing 11:10 – Genetic testing 13:08 – Innovative diagnostics

Dr. John Granton, a critical care and transplant physician at Toronto General Hospital, shares his journey in pulmonary hypertension and lung transplantation, detailing the groundbreaking advancements in transplant technology. He discusses the evolution of lung preservation methods, the challenges of chronic rejection, and the hope for longer-lasting transplants. With a passion for improving patient outcomes, Dr. Granton envisions a future where transplant becomes obsolete—replaced by treatments that cure underlying diseases. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. @UHN @teamphhope #phawareMD #PHILD #transplant @phacanada

In the second episode of our Rare Lung Diseases podcast mini-series, host Saranya Ravindran delves into the complexities of pulmonary arterial hypertension (PAH) with Neal Chaisson, Assistant Professor of Medicine at the Cleveland Clinic. Chaisson shares insights into why PAH remains under-recognised, the nuances of detection and diagnosis, and what the latest advancements mean for patients and clinicians. The discussion covers everything from early warning signs to future directions in PAH management and research. 

In the second episode of our Rare Lung Diseases podcast mini-series, host Saranya Ravindran delves into the complexities of pulmonary arterial hypertension (PAH) with Neal Chaisson, Assistant Professor of Medicine at the Cleveland Clinic. Chaisson shares insights into why PAH remains under-recognised, the nuances of detection and diagnosis, and what the latest advancements mean for patients and clinicians. The discussion covers everything from early warning signs to future directions in PAH management and research.  Timestamps:   Part 1:   01:00 – What is PAH  02:34 – Risk factors  04:21 – Misdiagnoses  07:13 – Pathophysiology  10:44 – World Symposium classification 

Thank you for listening to The Peptide Podcast. If you enjoyed the show and want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going. Today, we're focusing on an often-overlooked peptide called VIP, short for Vasoactive Intestinal Peptide. The name might sound technical, but this peptide plays some important roles in the body. It helps regulate inflammation, supports nerve function, improves blood flow by relaxing blood vessels, and may even have benefits for things like chronic pain, including back pain. Let's get into it. What is VIP? We've talked about VIP before on a previous podcast, but it's been awhile and I'd like to start with the basics as a refresher.  VIP is a 28-amino acid neuropeptide that acts like a signaling molecule in both the central and peripheral nervous systems. Think of it like a chemical messenger that can influence a lot of different body systems. VIP belongs to the glucagon/secretin peptide superfamily, and it's found throughout the body, including your brain, intestines, lungs, and immune cells. Now, what does VIP actually do? Well it does quite a bit. VIP works by binding to specific receptors on cells—called VPAC1 and VPAC2—which trigger a chain reaction inside the body through something known as the cyclic AMP pathway. Once activated:  It relaxes smooth muscles, which helps open up blood vessels (vasodilation) and airways (bronchodilation) It stimulates secretion of water and electrolytes in places like the gut and pancreas—so yes, it helps with digestion too It's a major immune modulator, calming inflammation by regulating immune cell behavior  Neuroprotective role, supporting the survival and adaptability of neurons VIP in Medicine – What's the Buzz? VIP has been studied in a variety of conditions. Inflammatory diseases like rheumatoid arthritis and Crohn's Neurodegenerative conditions like Alzheimer's and Parkinson's Autoimmune diseases like osteoarthritis Respiratory conditions like pulmonary arterial hypertension (PAH), asthma, and chronic obstructive pulmonary disease (COPD) or due to mold toxicity But today, we're zooming in on something more tangible for a lot of people—back pain. VIP and Back Pain – What Do We Know? Let's get into the science here. VIP has recently caught attention for its potential role in intervertebral disc degeneration, which is one of the top causes of chronic low back pain. A 2024 study found that VIP receptors were significantly reduced in degenerated human discs—which is kind of a red flag. When VIP was given to mice for four weeks, researchers saw slowed degeneration, better structural proteins like aggrecan, and overall healthier discs on imaging. Promising, right? But here's the catch—this was a preclinical animal study. We still need human trials to confirm it works outside the lab. VIP and Joint Pain And when it comes to VIP and joint pain, there's a bit more research on VIP and osteoarthritis, especially when the spine is involved. In OA models, VIP was shown to lower pro-inflammatory cytokines—those molecules that contribute to pain and make joints hurt. But here's where it gets complicated: some studies report that VIP accumulation in joints might actually worsen pain. So... it's a bit of a paradox. So what's the takeaway? VIP can be helpful—but its role in pain management seems to depend on how much, where, and what kind of pain we're talking about. VIP in Peptide Therapy – Real-World Use? In peptide clinics—especially those using integrative or regenerative medicine approaches—VIP is sometimes part of treatment protocols for nerve-related pain and inflammation. It's often paired with other peptides like BPC-157 and TB-500. You can find some clinics that list VIP as a go-to for chronic pain, including back pain. But here's the reality check, clinical data is limited, success is anecdotal, it's pricey and results can vary from person to person. So while VIP might help reduce inflammation and slow tissue degeneration, it's not a substitute for tried-and-true pain management peptides like BPC-157. Thank you for listening to The Peptide Podcast. If you enjoyed the show and want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going.  Until next time, be well, and as always, have a happy, healthy week.

Dr. Tijana Milinic and Lia Barros, DNP, from the University of Washington take a deep dive into the world of pulmonary arterial hypertension (PAH) clinical trials and discuss why diversity and inclusion matter. They explore the hidden biases in medical research and the real-world consequences of exclusion. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. @uwepidemiology  #phawareMD

Dr. Lana Melendres-Groves dives into her research on racial and ethnic disparities in PAH treatment. From differences in medication access to the role of social determinants of health, she explores how systemic barriers impact care and what steps can be taken to ensure equity and inclusivity in PAH management. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. @UNMHSC #phawareMD

Dr. Roham Zamanian, discusses the concept of "disease modification" in the treatment of pulmonary hypertension. He describes how this idea emerged from discussions with colleagues about the future of pulmonary hypertension therapies, and the potential for treatments to impact the underlying disease process beyond just reducing pulmonary artery pressures. This Special Edition Episode Sponsored by: Johnson & Johnson Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com #phawareMD @PHatStanford @docroham @JNJInnovMed    

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let's dive into the latest updates impacting clinicians and healthcare providers like you! Interested in a more traditional, text rundown? Check out the HCPFive! Top 5 Healthcare Headlines for June 16-22, 2025: Pemvidutide Shows Significant MASH Effects, Weight Loss at 24 Weeks in Phase 2b IMPACT Trial Topline phase 2b data show pemvidutide achieved significant rates of MASH resolution and fibrosis improvement alongside meaningful weight loss at 24 weeks, positioning it as a promising candidate for metabolic liver disease treatment. FDA Approves Belimumab (Benlysta) Autoinjector for Pediatric Lupus Nephritis The FDA approved a belimumab autoinjector for at-home subcutaneous use in children as young as five with active lupus nephritis, providing the first approved biologic self-injection option for pediatric SLE and LN. Phase 3 Trial Results Announced for Sotatercept-csrk in Pulmonary Arterial Hypertension Positive phase 3 results show sotatercept-csrk added to background therapy reduced time to clinical worsening events in adults with PAH, supporting its potential as an effective treatment for this high-risk population. Compass Pathways' COMP360 Psilocybin Shows Benefit in Phase 3 TRD Trial COMP360 psilocybin demonstrated a significant reduction in depression symptom severity in treatment-resistant depression, meeting the primary endpoint in a pivotal phase 3 trial. Once-Monthly Obesity Drug, MariTide, Achieves Weight Loss Up to 16% at 1 Year Phase 2 data indicate once-monthly MariTide induces substantial weight loss of up to 16% over one year, with additional improvements in glycemic control, highlighting its promise for obesity and type 2 diabetes management.

Bert's reading The Book of Form and Loneliness and Sally's been reading PAH!

Dr. Rodolfo Estrada, is a seasoned pulmonologists currently at UT Health San Antonio with significant experience in the management of patients with different forms of pulmonary hypertension. In this episode, Dr. Estrada will discuss the technology and clinical development behind YUTREPIA™ (treprostinil) inhalation powder and why it might be a good option for some PAH and PH-ILD patients. This Special Edition episode is sponsored by Liquidia. Please see the Important Safety Information following this podcast. The Prescribing Information and Instructions for Use for YUTREPIA (treprostinil) inhalation powder are available at YUTREPIA.com.  YUTREPIA is approved for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve the ability to exercise. Please see the Important Safety Information in the show notes. The Prescribing Information and Instructions for Use for YUTREPIA are available at YUTREPIA.com. Learn more about the INSPIRE study. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. #phawareMD #PHILD @Liquidia_Corp @REstradaMD @UTHealthSA IMPORTANT SAFETY INFORMATION Before you take YUTREPIA, tell your healthcare provider about all of your medical conditions, including if you: Have low blood pressure Have or have had bleeding problems Have asthma or chronic obstructive pulmonary disease (COPD) Are pregnant or plan to become pregnant. It is not known if this product will harm your unborn baby Are breastfeeding or plan to breastfeed. It is not known if this product passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. YUTREPIA and other medicines may affect each other. Especially tell your healthcare provider if you take: Medicines used to treat high blood pressure or heart disease Medicines that decrease blood clotting (anticoagulants) Water pills (diuretics) Gemfibrozil (Lopid®) or rifampin (Rimactane®, Rifadin®, Rifamate®, Rifater®) What are the possible side effects of YUTREPIA? This product can cause serious side effects, including: Low blood pressure (symptomatic hypotension). If you have low blood pressure, this product may lower your blood pressure more. Bleeding problems. This product may increase the risk of bleeding, especially in people who take blood thinners (anticoagulants). The most common side effects of YUTREPIA are cough, headache, throat irritation and pain, nausea, reddening of the face and neck (flushing), fainting or loss of consciousness, dizziness, diarrhea, and shortness of breath. Like other inhaled prostaglandins, you may have trouble breathing after taking YUTREPIA because it may cause the muscles around your airway to tighten (bronchospasm). These are not all the possible side effects. Call your doctor for medical advice about side effects or if you have trouble breathing. You may report side effects to the FDA at www.fda.gov/MedWatch or call 1–800-FDA-1088. The risk information provided here is not comprehensive. To learn more about YUTREPIA, talk with your healthcare provider. Please see Full Prescribing Information for YUTREPIA and Instructions for Use. For additional information, call 1–888–393–5732.

Magische Kenntnisse wegen eines Patrons? Oder einfach von Geburt an? Pah, das kann ja jeder! Du willst für deine Zauberkünste ackern! Dann ist der Magier das Richtige für dich. Der kleine Bücherwurm ist nämlich besonders fleißig, wenn es darum geht, die meisten Zauber des D&D Universums zu perfektionieren.Eberron: Forge of the Artificer auf Fantasywelt: https://www.fantasywelt.de/DD-Eberron-Forge-of-the-Artificer-HC-EN?wsa=4cc2bej17ga3h⁠⁠Alles zu D&D auf Fantasywelt:⁠⁠https://www.fantasywelt.de/Dungeons-Dragons?wsa=4cc2bej17ga3h⁠⁠#R2DnD #RoadtoDnD #DnDPodcast #DnDDeutsch #PenAndPaper

Seth Hall, MBA, RRT, takes listeners on a journey through the past, present, and future of inhaled therapies. Discover how these treatments have evolved, the life-changing benefits they offer, and the revolutionary technologies that could redefine outcomes for PAH and PH-ILD patients. This Special Edition episode is sponsored by Liquidia. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. #phawareMD #PHILD @Liquidia_Corp #PRINTTechnology 

TEX-TREK Mission 329: STAR TREK: DS9's "The Assignment" Back-Trekking RetrospectiveThis week we are diving back into the shadows of DS9 for a Keiko-centric thriller! The season 5 episode, "The Assignment," doesn't get talked about much, but it has a lot to offer. Join us as we discuss the eerie dynamics of Rosalind Chao playing her own hostage, the ominous reveal of the Pah-wraiths, O'Brien's psychological tension, and Rom once again showing how great of a guy he can be. Stan from Salon Trek joins Taylor and Fatheree as the guest this week.As always, available in both video and audio-only formats.Watch on YouTube:https://www.youtube.com/watch?v=W09pxPbA7WgGet RSS feed:https://anchor.fm/s/f37edb0c/podcast/rssApple Podcasts:https://podcasts.apple.com/us/podcast/tex-trek/id1495605753?uo=4Spotify:https://open.spotify.com/show/6mdZ030Klldxwn7SSc5PKp?si=3BOqsbQER9Ssfppqk7lofQ&fbclid=IwAR1M1uH_xBE1lYWcwQocoDzjoVSsLmCgBt08TCEYAltwIH3MPC0S60bMCsEJoin our Discord server:https://discord.gg/YXPeRyQh7ySupport us on Patreon:https://www.patreon.com/txtrekStar Trek: Deep Space Nine, Season 5 Episode 5"The Assignment"Teleplay by Bradley Thompson & David WeddleStory by Robert Lederman & David R. LongDirected by Allan KroekerAfter returning from the Fire Caves on Bajor, Keiko's body is controlled by an alien lifeform that forces her husband O'Brien to do its bidding or else face the death of his wife.http://www.facebook.com/textrekhttps://www.instagram.com/txtrek/http://twitter.com/TxTrekhttps://www.tiktok.com/@txtrekEmail: fathereeactual@tex-trek.com

 Zapraszamy na środowe wydanie "Onet Rano.", które poprowadzi Odeta Moro. Jej gośćmi będą: Aleksandra Leo, Polska 2050; Maciej Bagiński, prezes PAH; Leon Krześniak, wokalista; Monika Masalska i Szymon Masalski, autorzy książki "Nad wodę. Mikrowyprawy z Warszawy". Z kolei w części "Onet Rano. #WIEM" gościem Dominiki Długosz będzie Edward Augustyn, szef działu religijnego „Tygodnika Powszechnego”.

Dr. Ron Zolty delves into groundbreaking advancements in treating pulmonary arterial hypertension. From the historical use of vasodilators to the revolutionary promise of sotatercept and seralutinib, Dr. Zolty unpacks how science is moving closer to halting—and possibly even reversing—PAH. This Special Edition episode is sponsored by Gossamer Bio. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. #phawareMD @UNMCCOM @NebraskaMed @GossamerBio #clinicaltrial #PROSERA 

Returning for a second study this month, the JHLT Digital Media Editors invite first author Charlotte Van Edom to discuss the paper, “Apixaban plasma levels in patients with HeartMate 3 support.” As a cardiologist in training and a PhD candidate at the University Hospitals Leuven in Belgium, Van Edom's work focuses on hemocompatibility and mechanical circulatory support, covering both short-term and long-term support. The episode explores: The evolution of the use and understanding of direct oral anticoagulants (DOACs) during LVAD support, including the increased focus on Factor Xa inhibitors Encouraging findings from the study and what clinical practices might need to change if introducing apixaban Additional studies exploring DOACs in LVAD patients For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt. Treat or research pulmonary vascular diseases? Check out the first April episode for a study on sotatercept in PAH patients. Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

Latest Developments in the Treatment of Pulmonary Arterial Hypertension    Guest: Robert P. Frantz, M.D. Host: Kyle Klarich, M.D.   Pulmonary arterial hypertension (PAH) is a serious disease manifested by vasoconstriction and obliteration of the pulmonary arterial vasculature resulting in rise in pulmonary artery pressure and resistance and culminating in right heart failure. Listeners will learn more about traditional treatments for PAH, as well as new anti-proliferative therapies in active clinical investigation, and what that means for the future of treatment.   Topics Discussed: What is most new and exciting in the treatment of pulmonary arterial hypertension? What monitoring is necessary in order to safely use sotatercept? What future developments do you envision for the field of pulmonary hypertension?   Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV and @MayoCVservices. LinkedIn: Mayo Clinic Cardiovascular Services Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode. Podcast episode transcript found here.

Eric Austin, MD, MSCI discusses early detection among people who are at risk of pulmonary arterial hypertension (PAH), particularly those who would have genetic susceptibility, or who may have congenital heart disease, or who may have connective tissue disease or other features that would make them more at risk of developing pulmonary arterial hypertension than the rest of the population. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com #phawareMD @VUMCDiscoveries @pphnet @VUMCchildren

Sandra M. Oliver-McNeil, DNP, ACNP-BC, FACC, JACC: Case Reports Deputy Editor, is joined by author Liam S. Flanagan, MD discussing this study from Flanagan et al presented at ACC.25 and published in JACC: Case Reports. Pulmonary arterial hypertension (PAH) has a diverse range of etiologies and carries significant morbidity and mortality. Here, a 45-year-old female presented with shortness of breath and was found to be in acute right heart failure due to PAH. Exam demonstrated features of scurvy. She initially required vasopressors, supplemental oxygen therapy, and PAH therapies but rapidly improved with vitamin C supplementation.

Returning for a second study this month, the JHLT Digital Media Editors conduct an internal discussion on the paper, “Safety and efficacy of riociguat in patients with pulmonary arterial hypertension and cardiometabolic comorbidities: Data from interventional clinical trials.”   The episode explores: The aging PAH population and the new comorbidities that must be considered in research How the study augments and expands on recent standards, like the 2022 ESC/ERS guidelines for pulmonary hypertension Limitations on the study and opportunities for future research For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt.   Those on lung transplant teams should check the previous episode for a study on how rewarming ischemia time affects lung transplant outcomes.   Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.  

This CME program, hosted by Jean Elwing, MD, of the University of Cincinnati College of Medicine provides an overview of the latest clinical research about PAH presented at CHEST 2024.PAH is a rare, progressive disorder characterized by high blood pressure in the pulmonary arteries. Symptoms of PAH include shortness of breath (dyspnea) especially during exercise, chest pain, and fainting episodes. The progressive nature of this disease means that an individual may experience only mild symptoms at first, but will eventually require treatment and medical care to maintain a reasonable quality of life. There are numerous treatment options and options in development for persons with PAH and it is imperative clinicians who manage these patients stay up-to-date on the latest clinical research. Target AudienceThis activity has been designed to meet the educational needs of physicians specializing in pulmonology, cardiology, rheumatology, and radiology. Other members of the care team may also participate.Learning ObjectivesDescribe the latest research being presented to better manage people with PAH and its clinical relevance.CME CreditTo obtain credit, visit https://checkrare.com/learning/p-pah-clinical-research-highlights-chest-2024/Faculty/ DisclosureAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Dr. Elwing discloses the following relevant financial relationships with ineligible companies:Advisory Board Consultant: United Therapeutics, Aerovate Therapeutics, Gossamer Bio, Liquidia, Merck, Janssen/Actelion/Johnson & Johnson, Lung LLC, PulmovantGrant/Research Support: United Therapeutics, Gossamer Bio, Bayer, Acceleron/Merck, Altavant Sciences, Aerovate Therapeutics, Pharmosa Biopharm/Liquidia, Actelion/Janssen/Johnson & Johnson, Lung LLC, PulmovantSpeaking Honorarium: United TherapeuticsPlanners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information.The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically and draw conclusions only after careful consideration of all available scientific information.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.PrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm  For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactPlease contact: CEServices@academycme.org for any comments or questions.;Copyright © 2025. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

On this episode of JHLT: The Podcast, the Digital Media Editors invite lead author Jan Van Slambrouck, MD, to discuss the paper, “The effect of rewarming ischemia on tissue transcriptome and metabolome signatures: A clinical observational study in lung transplantation.”   Dr. Van Slambrouck is a general surgeon who's just finished his PhD training at the KU Leuven lab of respiratory disease and thoracic surgery in Belgium.   The episode explores:  How rewarming ischemia time (RIT) affects donor lungs, especially on the molecular level The pace of rewarming and how prior literature prepared the team to track and evaluate it Clinical strategies to reduce RIT and directly address molecular changes   For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt.   Those involved in the pulmonary vascular disease space should tune in again later this month for a study on the safety and efficacy of riociguat in patients with PAH.   Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

Jen Cueva, a pulmonary hypertension patient of almost two decades, discusses her diagnosis, her advocacy work, and how she uses writing to support the pulmonary hypertension community. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. @PulmonaryNews

Canadian resident, Stephen Gariepy, was diagnosed with Chronic Thromboembolic Pulmonary Hypertension (CTEPH) in 2018. After initially being active in senior hockey, his condition worsened, leading to difficulty breathing and performing daily tasks. Gariepy continues to live with this rare and terminal disease, adapting to the limitations it imposes on his daily life. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. @phacanada 

On this episode, we evaluate current guidelines and evidence-based treatment strategies for managing pulmonary arterial hypertension. We compare and contrast the efficacy, safety profiles, and appropriate use of targeted PAH therapies, adjunct treatments, and patient monitoring techniques.  Cole and I are happy to share that our listeners can claim ACPE-accredited continuing education for listening to this podcast episode! We have continued to partner with freeCE.com to provide listeners with the opportunity to claim 1-hour of continuing education credit for select episodes. For existing Unlimited (Gold) freeCE members, this CE option is included in your membership benefits at no additional cost! A password, which will be given at some point during this episode, is required to access the post-activity test. To earn credit for this episode, visit the following link below to go to freeCE's website: https://www.freece.com/ If you're not currently a freeCE member, we definitely suggest you explore all the benefits of their Unlimited Membership on their website and earn CE for listening to this podcast. Thanks for listening! If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable PowerPoint slides for each lecture. If you purchase an annual membership, you'll also get a free digital copy of High-Powered Medicine 3rd edition by Dr. Alex Poppen, PharmD. HPM is a book/website database of summaries for over 150 landmark clinical trials.You can visit our Patreon page at the website below:  www.patreon.com/corconsultrx We want to give a big thanks to Dr. Alex Poppen, PharmD and High-Powered Medicine for sponsoring the podcast..  You can get a copy of HPM at the links below:  Purchase a subscription or PDF copy - https://highpoweredmedicine.com/ Purchase the paperback and hardcover - Barnes and Noble website We want to say thank you to our sponsor, Pyrls. Try out their drug information app today. Visit the website below for a free trial: www.pyrls.com/corconsultrx We also want to thank our sponsor Freed AI. Freed is an AI scribe that listens, prepares your SOAP notes, and writes patient instructions. Charting is done before your patient walks out of the room. You can try 10 notes for free and after that it only costs $99/month. Visit the website below for more information: https://www.getfreed.ai/  If you have any questions for Cole or me, reach out to us via e-mail: Mike - mcorvino@corconsultrx.com Cole - cswanson@corconsultrx.com

In ep 108 of “How Do You Say That?!” sponsored by britishvoiceover.co.uk, Melissa Sinden joins Sam and Mark to talk about the irony of being asked to play an AI voice, how sessions with lots of people involved can get quite unruly, and how to sound natural when you're playing the part of a voice actor!Our VO question this week is all about how you create a rounded, three-dimensional character for animation.Get involved! Have you got a Wildcard suggestion that we should try or an idea for the show? Send it to us via Mark or Sam's social media or email it directly to podcast@britishvoiceover.co.ukScript 1Right... I'm just getting my characterisation sorted... do you want to hear my thoughts? So, with the main course... our seven nut ‘nut' roast... I'm thinking I'm a nut connoisseur, but I not only embrace the taste of the nuts, but I also travel to where they're produced and soak in the local culture, which gives me an insight into the source of their taste... and as for the vegetables... they'll be picked by students on summer vacation, working on organic farms in Norfolk... they'll be first and maybe second year students, from all around the world... How does that sound?Script 2MVO: (vintage style) In my day motor vehicles had keys not buttons and they didn't need plugging in! When you get a ding, dent, chip or scratch in your techo Tesla, who can repair it now ask! Robots? Pah.FVO: (modern voice of a smart AI) Prestige cars can be repaired at A and B Vehicle repairs. They are manufacturer approved for Audi, Mercedes, BMW and now also Tesla. Does that answer your question?MVO: Who said that? what witchery is this?!FVO: Go direct to A and B Vehicle Repairs; where accidents unhappen.We'd love your feedback - and if you listen on Apple Podcasts or Spotify, hit the follow button today!**Listen to all of our podcasts here - you can also watch on YouTube, or say to your smart speaker "Play How Do You Say That?!"About our guest: Melissa is the child of a pair of opera singers and has been a voice actor for many years - despite being only 39!! She trained as an actor but went straight into voicing.As well as corporate and commercial, she was also an animation voice - Jess the Cat's meow in Postman Pat as well as Strange Hill High, Little Monsters AND a background clucker in the first Chicken Run film! Melissa has also done tons of radio drama over the years as well as BBC Radio 4 short stories, book extracts and poems. Melissa finally went back into in vision acting about 15 years ago - programmes like Shameless, Brassic, Vera, Corrie and Emmerdale, as well as theatre and she writes and does public speaking gigs! Melissa's VocalPoint Website Resources: Click here for the Wildcard Generator and don't forget to think of an action your character can be doing!Mark's demos & contact details:

Jolie Lizana is a pulmonary hypertension (PH) survivor and advocate. Despite enduring severe heart failure and lengthy hospitalizations, Jolie credits her medical background, determination, and the love for her child for pushing her to survive and adapt. Jolie now raises awareness through her website, www.breathtakingawareness.com, and has contributed to creating EMS protocols for PH patients, showing her dedication to empowering others with hope and resources. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com.

Allison Feenstra shares her transformative journey from being an active, independent young woman to navigating life with pulmonary hypertension (PH). She recounts how a sudden blackout led to hospital visits and the discovery of the condition, stemming from complications related to prolonged bed rest and birth control medication. Allison candidly discusses how she underwent a significant surgery and persevered through a high-risk pregnancy, ultimately becoming a mother. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. @phacanada

Welcome, weary adventurers, to another celestial installment of the RPGBOT.Podcast! In this episode, our hosts take a divine deep dive into the luminous layers of Mount Celestia, the lawful good paradise of the D&D multiverse, where angelic beings reign supreme, the paperwork never stops, and even heaven has a dress code. Links 2014 Dungeon Master's Guide (affiliate link) 2024 Dungeon Master's Guide (affiliate link) Mordenkainen's Tome of Foes (affiliate link) Forgotten Realms Wiki - Celestia The Roof is on Fire The Bad Touch What's Inside This Episode? Prepare for an unholy amount of lawful good as our hosts grapple with questions like: Is Mount Celestia just an exclusive afterlife country club? The ultimate "gated community," where only the most virtuous souls get a keycard and an HOA compliance form. Do Celestials ever take a break? Or are they stuck in an eternal grind to keep their goodness rating at a solid 10/10? Why does the seventh layer feel like the VIP lounge of the cosmos? No one comes back to tell the tale—are they ascending to ultimate bliss or just getting locked in divine HR meetings forever? Is Bahamut's realm the fantasy equivalent of an armored Renaissance Faire? A blend of knightly virtue, dragon-sized bureaucracy, and the world's most rigid chivalry standards. What's with the mysterious black domes? Are they heavenly zen gardens or celestial prisons? And why do they sound like the plot of a horror movie? Heaven, but Make It Complicated The discussion takes unexpected turns as the hosts compare D&D's Mount Celestia with Pathfinder's Heaven, exploring celestial beings, alignment shenanigans, and the sheer logistics of running a flawless divine realm (spoiler: it's harder than it looks). From beachfront property in the first layer to the moral implications of ascending through good deeds, the conversation proves that even perfection has a few cracks. But wait, there's more! Comedic interludes featuring celestial court jesters, the trials of divine pronunciation (is it Pay-lore or Pah-lore?), and the baffling existence of heavenly bouncers. A light roasting of the celestial bureaucracy, because even angels probably have to fill out divine TPS reports. A deep-dive into morality, questioning whether lawful good is just neutral good with extra paperwork. Final Verdict? Celestia might be a beacon of goodness, but our hosts aren't convinced it's the paradise it claims to be. Between the divine bureaucracy, alignment gatekeeping, and oddly exclusive policies, they make a compelling case for why sometimes, chaotic neutral might be the way to go. Tune in to this hilariously insightful episode where philosophy meets comedy, and the afterlife gets a much-needed reality check! If you enjoy the show, please rate and review us on Apple Podcasts, Spotify, or your favorite podcast app. It's a quick, free way to support the podcast, and helps us reach new listeners. If you love the show, consider joining us on Patreon, where backers at the $5 and above tiers get ad free access to RPGBOT.net and the RPGBOT.Podcast, can chat directly to members of the RPGBOT team and community on the RPGBOT.Discord, and can join us for live-streamed recordings. Support us on Amazon.com when you purchase products recommended in the show at the following link: https://amzn.to/3NwElxQ How to Find Us: In-depth articles, guides, handbooks, reviews, news on Tabletop Role Playing at RPGBOT.net Tyler Kamstra Twitter: @RPGBOTDOTNET Facebook: rpgbotbotdotnet Bluesky:rpgbot.bsky.social Ash Ely Professional Game Master on StartPlaying.Games Twitter: @GravenAshes YouTube@ashravenmedia Randall James @JackAmateur Amateurjack.com Producer Dan @Lzr_illuminati  

Welcome, weary adventurers, to another celestial installment of the RPGBOT.Podcast! In this episode, our hosts take a divine deep dive into the luminous layers of Mount Celestia, the lawful good paradise of the D&D multiverse, where angelic beings reign supreme, the paperwork never stops, and even heaven has a dress code. Links 2014 Dungeon Master's Guide (affiliate link) 2024 Dungeon Master's Guide (affiliate link) Mordenkainen's Tome of Foes (affiliate link) Forgotten Realms Wiki - Celestia The Roof is on Fire The Bad Touch What's Inside This Episode? Prepare for an unholy amount of lawful good as our hosts grapple with questions like: Is Mount Celestia just an exclusive afterlife country club? The ultimate "gated community," where only the most virtuous souls get a keycard and an HOA compliance form. Do Celestials ever take a break? Or are they stuck in an eternal grind to keep their goodness rating at a solid 10/10? Why does the seventh layer feel like the VIP lounge of the cosmos? No one comes back to tell the tale—are they ascending to ultimate bliss or just getting locked in divine HR meetings forever? Is Bahamut's realm the fantasy equivalent of an armored Renaissance Faire? A blend of knightly virtue, dragon-sized bureaucracy, and the world's most rigid chivalry standards. What's with the mysterious black domes? Are they heavenly zen gardens or celestial prisons? And why do they sound like the plot of a horror movie? Heaven, but Make It Complicated The discussion takes unexpected turns as the hosts compare D&D's Mount Celestia with Pathfinder's Heaven, exploring celestial beings, alignment shenanigans, and the sheer logistics of running a flawless divine realm (spoiler: it's harder than it looks). From beachfront property in the first layer to the moral implications of ascending through good deeds, the conversation proves that even perfection has a few cracks. But wait, there's more! Comedic interludes featuring celestial court jesters, the trials of divine pronunciation (is it Pay-lore or Pah-lore?), and the baffling existence of heavenly bouncers. A light roasting of the celestial bureaucracy, because even angels probably have to fill out divine TPS reports. A deep-dive into morality, questioning whether lawful good is just neutral good with extra paperwork. Final Verdict? Celestia might be a beacon of goodness, but our hosts aren't convinced it's the paradise it claims to be. Between the divine bureaucracy, alignment gatekeeping, and oddly exclusive policies, they make a compelling case for why sometimes, chaotic neutral might be the way to go. Tune in to this hilariously insightful episode where philosophy meets comedy, and the afterlife gets a much-needed reality check! If you enjoy the show, please rate and review us on Apple Podcasts, Spotify, or your favorite podcast app. It's a quick, free way to support the podcast, and helps us reach new listeners. If you love the show, consider joining us on Patreon, where backers at the $5 and above tiers get ad free access to RPGBOT.net and the RPGBOT.Podcast, can chat directly to members of the RPGBOT team and community on the RPGBOT.Discord, and can join us for live-streamed recordings. Support us on Amazon.com when you purchase products recommended in the show at the following link: https://amzn.to/3NwElxQ How to Find Us: In-depth articles, guides, handbooks, reviews, news on Tabletop Role Playing at RPGBOT.net Tyler Kamstra Twitter: @RPGBOTDOTNET Facebook: rpgbotbotdotnet Bluesky:rpgbot.bsky.social Ash Ely Professional Game Master on StartPlaying.Games Twitter: @GravenAshes YouTube@ashravenmedia Randall James @JackAmateur Amateurjack.com Producer Dan @Lzr_illuminati  

On the 28th anniversary of her PH diagnosis, Jodi Berry shares her journey of living with pulmonary hypertension. Despite facing an initial prognosis of only a few years to live, Jodi's determination and the support of her family, friends, and healthcare professionals helped her manage her condition while maintaining an active lifestyle. Over time, advancements in treatments and her proactive participation in clinical trials provided hope and improved her quality of life. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. @phacanada

Nurse Practitioner, Janette Reyes, from the Pulmonary Hypertension Program at the Hospital for Sick Children shares her extensive experience caring for pediatric patients with pulmonary hypertension. Reyes discusses the unique challenges and developmental considerations involved in treating children from infancy through their teenage years, as they transition to adulthood. Reyes also touches on the emotional and social struggles these young patients face, such as bullying and anxiety, and highlights the role of the multidisciplinary team in supporting their mental well-being. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. @phacanada

Jennifer Howard's inspiring story is one of resilience and hope in the face of immense challenges. Diagnosed with idiopathic pulmonary arterial hypertension (IPAH) in July 2019 after a long and frustrating path to answers, Jennifer faced the daunting reality of living with a chronic illness requiring continuous IV medication through a pump. Despite the overwhelming nature of her diagnosis, Jennifer discovered an inner strength she never knew she had. With a focus on living life to the fullest, she learned to navigate both the bad days and the good, embracing moments that brought her happiness and refusing to let despair take root. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. @phacanada  

Winterpause? Pah! Schon in der zweiten Januarwoche geht es weiter mit der Fußball-Bundesliga. Da darf natürlich eine neue Folge Bohndesliga nicht fehlen! Wir starten in das neue Jahr mit der Besprechung des 16. Spieltags. Nils, Etienne, Niko und der sich in Quarantäne befindende Tobi analysieren den Spieltag in all seiner epischen Breite. Los geht es mit den beiden Top-Duellen des Spieltags. Am Samstagabend sicherte sich der FC Bayern München die Hinrundenmeisterschaft. Wie souverän der Sieg über Borussia Mönchengladbach wirklich war - darüber streiten sich die Gelehrten. Auf jeden Fall haben die Bayern einen weiteren Schritt Richtung Titel gemacht. Dabei hat sich auch Bayer Leverkusen schadlos gehalten. Die Werkself hatte das große Glück, dass Borussia Dortmund zu wenig Aspirin-Tabletten zur Hand hatte. Gleich die gesamte Abwehr fiel krankheitsbedingt aus. Die neu zusammengewürfelte Viererkette der Dortmunder schenkte sich die Tore praktisch selber ein. Wie ist der Auftritt der Schwarzgelben zu bewerten? Wir besprechen aber natürlich auch alle anderen Partien des 16. Spieltags. Nils und Etienne waren live im Millerntorstadion, als Eintracht Frankfurt mit Müh und Not den FC St. Pauli besiegte. Wie fällt ihr Fazit aus? Und was wird aus der Eintracht, sollte Omar Marmoush tatsächlich nach Manchester wechseln? Außerdem im Fokus: Union Berlins Protest über das DFB-Urteil, die Rückkehr von Xavi Simons bei RB Leipzig und der Mercedes Benz Junior Cup in Sindelfingen!

Kaitlyn Salonga shares her journey of resilience and advocacy while living with pulmonary hypertension (PH). Kaitlyn recounts her fight for personal autonomy, including a successful battle to secure surgery for her reproductive health after initial denials due to weight and health concerns. Through her triumphs, she highlights the importance of advocating for oneself in the face of medical and societal challenges. Her story is a powerful testament to embracing one's identity, breaking down stigma, and showing that life with PH can be fulfilling and bold. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. @phacanada

Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in the Pharma and Biotech world.Roche has recently finalized a new deal in China valued at up to $1 billion for an antibody-drug conjugate. However, Neumora's depression drug trial has unfortunately not yielded successful results. Additionally, Sangamo has experienced a setback by losing a partnership with Pfizer in hemophilia gene therapy. On a more positive note, Axsome has released mixed data from Alzheimer's trials but still plans to move forward with filing for FDA approval.In other recent developments, Merck's PAH drug and BMS' Opdivo injection have received regulatory greenlights. It's important to note that there are currently job opportunities available in various pharmaceutical companies for those looking to make a career move in the industry.Looking ahead to 2024, the neurobiopharma industry has been characterized as a rollercoaster of ups and downs.

Tanya Stinson shares her journey of being diagnosed with pulmonary hypertension (PH) after persistent symptoms and misdiagnoses. Her struggle highlights the difficulty of finding the right diagnosis and the emotional toll of living with a rare, chronic disease. Tanya's experience underlines the fear, mental challenges, and hope intertwined in navigating PH, inspiring others to seek support and find solace in community, showing that even in isolation, they are not alone. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. @phacanada

Hall Skaara, a resilient PH patient and founder of the Norwegian Association for Pulmonary Hypertension, recounts his 19-year journey living with idiopathic pulmonary hypertension. He shares how he transformed the challenges of the pandemic into an innovative opportunity by helping create the Bel Air Center, a virtual global PH community space. The Bel Air Center aims to foster global connections, support, and resources for patients, caregivers, and healthcare professionals. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. @EuropePHA 

Cynthia Neilson shares her journey as a mother raising her daughter Claire, who was diagnosed with pulmonary arterial hypertension (PAH) at a young age. Cynthia recounts the challenges she faced navigating the medical system, the emotional toll of dealing with an unexpected diagnosis, and the difficulties of balancing family life while ensuring her daughter received the best possible care. Cynthia emphasizes the value of connection, resilience, and advocacy for families dealing with rare diseases. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. @phacanada

W ubiegłym tygodniu między Izraelem a Hezbollahem ogłoszono zawieszenie broni, które w założeniu miało przerwać trwające od kilku tygodni walki w Libanie i Izraelu. Zawieszenie broni zostało jednak obłożone warunkami, które pokazują, że obie strony pozostają w gotowości do walki. Co więcej, już po jego wprowadzeniu w życie dochodziło do wymiany ognia między walczącymi stronami. Dlaczego do tego zawieszenia broni doszło w tym momencie? Czy Izraelczycy osiągnęli deklarowane cele strategiczne i taktyczne swojej operacji na terytorium północnego sąsiada? Czy Hezbollah jest na tyle osłabiony, że libańska armia będzie w stanie kontrolować całe terytorium kraju cedrów? O tym opowiada mi dr Agnieszka Bryc z Uniwersytetu Mikołaja Kopernika w Toruniu. Odcinek zaczynamy jednak od rozmowy o sytuacji humanitarnej w Libanie i działalności Polskiej Akcji Humanitarnej. Prowadzone od kilku lat centrum GLOW świadczące przede wszystkim usługi edukacyjne dla młodszego pokolenia Libańczyków zostało uszkodzone wskutek działań wojennych. Jak to wpłynie na działalność PAH w kraju i jak PAH i inne organizacje humanitarne przygotowują się do nadchodzącej wielkimi krokami zimy? O tym mówi mi Helena Krajewska, rzeczniczka prasowa Polskiej Akcji Humanitarnej.

Natalie Roy is a double lung transplant survivor living in Canada. She was diagnosed with pulmonary arterial hypertension (PAH) in 2005 and received her transplant in 2017. . After her successful transplant seven years ago, Natalie experienced a difficult initial recovery but felt amazing once she started healing. The first two years were cautious, but she was able to achieve many milestones she never thought possible, including getting married, playing sports, and changing careers. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. @phacanada 

Maureen Harper, a CTEPH patient from Canada, shares her journey with this rare condition. She initially thought she had an infection in her leg, but further tests revealed enlarged pulmonary arteries and multiple blood clots in her lungs. After being diagnosed with pulmonary hypertension, she underwent a complex surgery in Toronto to attempt to remove the clots. Maureen continues to work full-time as a pharmacy technician, remains active with her family and Girl Guide unit, and maintains a positive outlook, choosing to focus on the positives rather than dwell on the negatives. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. @phacanada 

Lynette Chambers, a 9-year PAH (pulmonary arterial hypertension) patient, has also been diagnosed with pulmonary fibrosis (PF). She shares her journey, from struggling with daily activities to being admitted to the hospital with severely low oxygen levels. Lynette discusses the emotional challenges of facing a terminal illness and the difficulty of balancing work and family time. Despite the hard reality, Lynette emphasizes the importance of gratitude, making others feel better, and being the best version of oneself. She finds strength in her family, especially her grandchildren, and strives to create lasting memories and make a positive impact on those around her. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. @phacanada

John Kingrey, MD, Director of the @integrishealth Pulmonary Hypertension (PH) Center of Oklahoma and PH patient, Nicole Fitzgerald, discuss the importance of the physician-patient relationship as it relates to participation in clinical trials including the Phase 2 TORREY Study (now the Phase 3 PROSERA Study). #GossamerBioPartner #sponsored Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com.

In this episode of the podcast we speak to Steve Smith, a patient advocate who is living with Pulmonary Arterial Hypertension (PAH), a rare and progressive condition characterized by narrowing of the blood vessels in the heart and lungs. Steve is a college administrator and avid theater participant who uses his PAH story to connect with others, believing that open communication is key to the patient experience.   Hear More About Steve and Other PAH patients: OutnumberPAH.com   Editor's Note: Chronic conditions and rare diseases don't discriminate. Patient Worthy and our partners are interested in amplifying the voices of those from all identities and backgrounds. If you have a story to share, learn more about how your voice can help spread awareness and inspire individuals from all walks of life here: getinvolved.patientworthy.com Outnumber PAH | Living With Pulmonary Arterial Hypertension Together we can outnumber PAH. Find resources for living with pulmonary arterial hypertension and learn from the stories of people in the PAH community.  

In this episode, David Lake a retired jet pilot, discusses his experience with pulmonary arterial hypertension, initially misdiagnosed as exercise-induced asthma. Lake also manages hemophilia, COPD, and irregular heartbeats, impacting his health significantly. Despite these challenges, he remains hopeful and active in his community and church. His story is a testament to resilience and the quest for better treatment through clinical trials. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware  Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com

Merriam-Webster's Word of the Day for June 17, 2024 is: apocryphal • uh-PAH-kruh-ful • adjective Something described as apocryphal is of doubtful authenticity; the term is often applied to stories or legends that are often repeated but likely not true. Apocryphal can also describe something resembling or relating to the Apocrypha, the ancient Jewish books that are not part of the Hebrew Bible but are considered canonical in Roman Catholic and Eastern Orthodox churches. In the biblical use, the word is often capitalized. // The legend of how the song was fully composed while the singer was in a deep fever state is probably apocryphal. See the entry > Examples: "There is a likely apocryphal story about how Michelangelo, upon getting criticism about David's nose being too big, climbed a ladder and pretended to chisel it." — Rita Bullwinkel, The New York Times, 27 Feb. 2024 Did you know? In biblical study, Apocrypha refers to books outside an accepted canon of scripture. In modern use, the term refers specifically to a group of ancient Jewish books that are not part of the Hebrew Bible but are considered canonical in Roman Catholic and Eastern Orthodox churches; Protestant churches follow Jewish tradition in considering these books noncanonical. Both apocrypha and apocryphal come, via Latin, from the Greek word apokrýptein, meaning "to hide (from), keep hidden (from)," which in turn comes from krýptein, "to conceal, hide." Both words entered English in the 16th century with their nonbiblical meanings, apocrypha referring to writings or statements of dubious authenticity, and apocryphal describing such things. Apocryphal is now the more common word. It most often describes an oft-repeated tale that is almost certainly not true.